# Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-i-study-and-biomarker-analysis-of-pyrotinib-a-novel-irreversible-pan-erbb/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Fei Ma,Qiao Li,Shanshan Chen,Wenjie Zhu,Ying Fan,Jiayu Wang,Yang Luo,Puyuan Xing,Bo Lan,Meiying Li,Zongbi Yi,Ruigang Cai,Peng Yuan,Pin Zhang,Qing Li,Binghe Xu |
| Citations | 234 |
| DOI | 10.1200/jco.2016.69.6179 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2613098450 |
| PMID | 28498781 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Puyuan Xing](https://scholariq.org/researchers/puyuan-xing/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.